{"id":11906,"date":"2021-03-16T16:20:18","date_gmt":"2021-03-16T10:50:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11906"},"modified":"2023-06-14T10:58:10","modified_gmt":"2023-06-14T05:28:10","slug":"pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta","title":{"rendered":"Merck, Gilead  teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta&#8217;s Kimyrsa"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a05b902361ce\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a05b902361ce\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta\/#Merck_Gilead_to_co-develop_combined_HIV_treatments\" >Merck, Gilead&nbsp; to co-develop combined HIV treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta\/#Sanofi_Regenerons_Libtayo_romps_through_in_Cervical_cancer\" >Sanofi, Regeneron\u2019s Libtayo romps through in Cervical cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta\/#Roche_set_to_acquire_GenMark_for_USD_18_B\" >Roche set to acquire GenMark for USD 1.8 B<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta\/#Melinta_Therapeutics_nabs_FDA_nod_for_Kimyrsa_for_Skin_infection\" >Melinta Therapeutics nabs FDA nod for Kimyrsa for Skin infection&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-merck-gilead-to-co-develop-combined-hiv-treatments\"><span class=\"ez-toc-section\" id=\"Merck_Gilead_to_co-develop_combined_HIV_treatments\"><\/span><strong>Merck, Gilead&nbsp; to co-develop combined HIV treatments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck and Gilead have announced a collaboration to investigate Gilead\u2019s investigational capsid inhibitor, lenacapavir, and Merck\u2019s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen.&nbsp;<\/p>\n\n\n\n<p>Both the drugs are first-in-class medicines in late-stage clinical trials, have long half-lives and have demonstrated clinical activity at low dosages in clinical trials. The molecules are under trials as a combination regimen being administered orally as well as intravenously with long-acting formulations. The trials to evaluate the combination therapy are expected to begin in the second half of 2021.<\/p>\n\n\n\n<p>The boon companionship shall help Gilead to bolster its <a href=\"https:\/\/www.delveinsight.com\/blog\/curing-hiv-with-gene-therapy\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">HIV<\/a> portfolio with the added advantage of turning a potential contender into an ally. Both the companies are heralded as the two of the biggest players in the HIV market and now will be sharing operational responsibilities, operating and manufacturing costs, as well as future profits, if the combination gets successful.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-regeneron-s-libtayo-romps-through-in-cervical-cancer\"><span class=\"ez-toc-section\" id=\"Sanofi_Regenerons_Libtayo_romps_through_in_Cervical_cancer\"><\/span><strong>Sanofi, Regeneron\u2019s Libtayo romps through in Cervical cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Overwhelmed with extremely favorable results, Sanofi and Regeneron Pharmaceuticals have halted the Phase III clinical trials evaluating their checkpoint inhibitor Libtayo (cemiplimab) in <a href=\"https:\/\/www.delveinsight.com\/blog\/cervical-cancer-market\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\">cervical cancer<\/a>. The move came after the&nbsp; Independent Data Monitoring Committee (IDMC) recommended the duo for the same, and now the companies are set to use the data for regulatory submissions.<\/p>\n\n\n\n<p>Going by the word from the company, Libtayo monotherapy is the first therapy that managed to improve OSS in women with recurrent or metastatic <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">cervical cancer<\/a> following progression on platinum-based chemotherapy in a Phase III trial.&nbsp;<\/p>\n\n\n\n<p>Not long ago, the USFDA had approved the monotherapy for patients with advanced non-small-cell lung cancer (NSCLC) whose tumors have high PD-L1 expression. Besides, the therapy is approved in two skin cancers, basal cell carcinoma and cutaneous squamous cell carcinoma. However, the companies wanted to launch the drug in a domain that is a little less crowded and competitive.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-set-to-acquire-genmark-for-usd-1-8-b\"><span class=\"ez-toc-section\" id=\"Roche_set_to_acquire_GenMark_for_USD_18_B\"><\/span><strong>Roche set to acquire GenMark for USD 1.8 B<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Roche has decided to take a bet worth USD 1.8 Billion on a US-based GenMark, a company that proffers molecular diagnostics solutions to detect multiple pathogens from a single sample. Roche has agreed to acquire all the outstanding shares of GenMark\u2019s common stock at a price of $24.05 per share in an all-cash transaction.&nbsp;<\/p>\n\n\n\n<p>The deal will help Roche add GenMark\u2019s syndromic panel testing portfolio to its diagnostic armamentarium. GenMark\u2019s Respiratory Pathogen Panels that can detect the most common viral and bacterial organisms causing upper respiratory infections, including <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\/?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">SARS-CoV-2<\/a>, would also be added to Roche\u2019s diagnostics kit.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The merger has been unanimously approved by the boards of both companies and is expected to be completed during the second quarter of 2021.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-melinta-therapeutics-nabs-fda-nod-for-kimyrsa-for-skin-infection\"><span class=\"ez-toc-section\" id=\"Melinta_Therapeutics_nabs_FDA_nod_for_Kimyrsa_for_Skin_infection\"><\/span><strong>Melinta Therapeutics nabs FDA nod for Kimyrsa for Skin infection&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Melinta Therapeutics has announced the USFDA approval of Kimyrsa (oritavancin) for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\" target=\"_blank\" rel=\"noreferrer noopener\">acute bacterial skin and skin structure infections<\/a> (ABSSSI) in adults. The therapy is a lipoglycopeptide antibiotic that delivers a complete course of therapy for ABSSSI in a single, one hour 1,200 mg infusion.<\/p>\n\n\n\n<p>The company used the data from Orbactiv\u2019s clinical trials that evaluated the drug in nearly 2,000 patients demonstrating clinical safety and efficiency through a single infusion with headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea reported as the most common side effects.&nbsp;<\/p>\n\n\n\n<p>The approval can prove to be a turning point for the company providing it with a much-needed boost since, in 2019, it filed for bankruptcy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, Gilead&nbsp; to co-develop combined HIV treatments Merck and Gilead have announced a collaboration to investigate Gilead\u2019s investigational capsid inhibitor, lenacapavir, and Merck\u2019s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen.&nbsp; Both the drugs are first-in-class medicines in late-stage clinical trials, have long half-lives and have demonstrated clinical activity at low dosages [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11909,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[3785,159,10830,1393,298,16913,16912,395],"industry":[17225],"therapeutic_areas":[17237,17231,17228,17278],"class_list":["post-11906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-absssi-therapeutic-market","tag-cervical-cancer","tag-covid-19","tag-gilead-sciences","tag-hiv-infection","tag-hiv-infection-market","tag-libtayo","tag-merck","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Merck\/Gilead in HIV market, Sanofi\/Regeneron\u2019s Libtayo in Cervical cancer<\/title>\n<meta name=\"description\" content=\"Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta&#039;s Kimyrsa\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\/Gilead in HIV market, Sanofi\/Regeneron\u2019s Libtayo in Cervical cancer\" \/>\n<meta property=\"og:description\" content=\"Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta&#039;s Kimyrsa\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T10:50:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T05:28:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/16161926\/Merck-Gilead-in-HIV-market.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck\/Gilead in HIV market, Sanofi\/Regeneron\u2019s Libtayo in Cervical cancer","description":"Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta","og_locale":"en_US","og_type":"article","og_title":"Merck\/Gilead in HIV market, Sanofi\/Regeneron\u2019s Libtayo in Cervical cancer","og_description":"Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-03-16T10:50:18+00:00","article_modified_time":"2023-06-14T05:28:10+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/16161926\/Merck-Gilead-in-HIV-market.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta","name":"Merck\/Gilead in HIV market, Sanofi\/Regeneron\u2019s Libtayo in Cervical cancer","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/16161926\/Merck-Gilead-in-HIV-market.jpg","datePublished":"2021-03-16T10:50:18+00:00","dateModified":"2023-06-14T05:28:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-merck-gilead-sanofi-regeneron-roche-genmark-melinta#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/16161926\/Merck-Gilead-in-HIV-market.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/16161926\/Merck-Gilead-in-HIV-market.jpg","width":772,"height":482,"caption":"Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta\u2019s Kimyrsa"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/03\/16161926\/Merck-Gilead-in-HIV-market-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ABSSSI Therapeutic Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cervical cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">gilead sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV infection market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Libtayo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ABSSSI Therapeutic Market<\/span>","<span class=\"advgb-post-tax-term\">Cervical cancer<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">gilead sciences<\/span>","<span class=\"advgb-post-tax-term\">HIV infection<\/span>","<span class=\"advgb-post-tax-term\">HIV infection market<\/span>","<span class=\"advgb-post-tax-term\">Libtayo<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Mar 16, 2021","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Mar 16, 2021 4:20 pm","modified":"Updated on Jun 14, 2023 10:58 am"},"featured_img_caption":"Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi\/Regeneron\u2019s Libtayo; Roche acquires GenMark; FDA okays Melinta\u2019s Kimyrsa\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11906"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11906\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11909"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11906"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11906"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}